Source: Health Products Regulatory Authority (IE) Revision Year: 2023 Publisher: Reckitt Benckiser Ireland Ltd, 7 Riverwalk, Citywest Business Campus, Dublin 24, Ireland
Hypersensitivity to the active substances or any of the excipients listed in section 6.1.
Patients who have previously shown hypersensitivity reactions (e.g. bronchospasm, asthma, rhinitis, angioedema or urticaria) in response to Ibuprofen, Acetylsalicylic Acid (Aspirin) or other non-steroidal anti-inflammatory drugs (NSAIDs).
Severe liver or kidney failure (see section 4.4).
Severe heart failure (NYHA Class IV).
History of gastrointestinal bleeding or perforation related to previous NSAIDs therapy.
Active, or history of recurrent peptic ulcer/haemorrhage (two or more distinct episodes of proven ulceration or bleeding).
Respiratory depression.
Chronic constipation.
Last trimester of pregnancy (See section 4.6 Pregnancy and Lactation).
Concomitant treatment with Monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping treatment (see section 4.5).
Use of codeine containing products is contraindicated in women during breastfeeding (see section 4.6).
In all paediatric patients (0-18 years of age) who undergo tonsillectomy and/or adenoidectomy for obstructive sleep apnoea syndrome due to an increased risk of developing serious and life-threatening adverse reactions (see section 4.4).
In children below the age of 12 years for the symptomatic treatment of cough and or cold due to an increased risk of developing serious and life-threatening adverse reactions.
In patients for whom it is known they are CYP2D6 ultra-rapid metabolisers.
Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to relieve symptoms.
Elderly: The elderly have an increased frequency of adverse reactions to NSAIDs especially gastrointestinal bleeding and perforation which may be fatal (see section 4.2).
Gastrointestinal effects: NSAIDs should be given with care to patients with a history of gastrointestinal disease (ulcerative colitis, Crohn’s Disease) as their condition may be exacerbated (see section 4.8 – undesirable effects).
GI bleeding, ulceration or perforation, which can be fatal, has been reported with all NSAIDs at any time during treatment, with or without any warning symptoms or a previous history of serious GI events.
The risk of GI bleeding, ulceration or perforation is higher with increasing NSAID doses, in patients with a history of ulcer, particularly if complicated with haemorrhage or perforation (see section 4.3), and in the elderly. These patients should commence treatment on the lowest dose available. Combination therapy with protective agents (e.g. misoprostol or proton pump inhibitors) should be considered for these patients, and also for patients requiring concomitant low dose aspirin, or other drugs likely to increase gastrointestinal risk (see below and 4.5).
Patients with a history of GI toxicity, particularly when elderly, should report any unusual abdominal symptoms (especially GI bleeding) particularly in the initial stages of treatment.
Caution should be advised in patients receiving concomitant medications which could increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors or anti-platelet agents such as aspirin (see section 4.5).
When GI bleeding or ulceration occurs in patients receiving Nurofen Plus, the treatment should be withdrawn.
Nurofen Plus tablets should be used with caution in patients with gastrointestinal disease. In patients receiving anti-coagulant therapy, prothrombin time should be monitored daily for the first few days of combined treatment.
Cardiovascular and cerebrovascular effects: Caution (discussion with doctor or pharmacist) is required prior to starting treatment in patients with a history of hypertension and/or heart failure as fluid retention and oedema have been reported in association with NSAID therapy.
Clinical studies suggest that use of ibuprofen, particularly at a high dose (2400mg/day) may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke). Overall, epidemiological studies do not suggest that low dose ibuprofen (e.g. ≤1200mg/day) is associated with an increased risk of arterial thrombotic events.
Patients with uncontrolled hypertension, congestive heart failure (NYHA II-III), established ischaemic heart disease, peripheral arterial disease, and/or cerebrovascular disease should only be treated with ibuprofen after careful consideration and high doses (2400 mg/day) should be avoided.
Careful consideration should also be exercised before initiating long-term treatment of patients with risk factors for cardiovascular events (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking), particularly if high doses of ibuprofen (2400 mg/day) are required
The tablets should be used with caution in patients with raised intracranial pressure or head injury.
Respiratory: Bronchospasm may be precipitated in patients suffering from or with a history of bronchial asthma or allergic disease. The possibility of cross-sensitivity with aspirin and other non-steroidal anti-inflammatory agents should be considered. If symptoms persist, consult your doctor.
Other NSAIDs: The use of Nurofen Plus with concomitant NSAIDs including cyclooxygenase-2 selective inhibitors should be avoided (see section 4.5).
SLE and mixed connective tissue disease: There is an increased risk of aseptic meningitis in patients with Systemic lupus erythematoses and mixed connective tissue disease using the active ingredients in this product (see section 4.8).
Renal: Renal impairment as renal function may deteriorate (see section 4.3 and 4.8). There is a risk of renal impairment in dehydrated children and adolescents.
Hepatic: Hepatic dysfunction (see section 4.3 and 4.8).
Severe Skin Reactions: Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs (see 4.8). Patients appear to be at highest risk of these reactions early in the course of therapy, the onset of the reaction occurring in the majority of cases within the first month of treatment. Acute generalised exanthematous pustulosis (AGEP) has been reported in relation to ibuprofen-containing products. Nurofen Plus should be discontinued at the first appearance of signs and symptoms of severe skin reactions such as skin rash, mucosal lesions, or any other sign of hypersensitivity.
Masking of symptoms of underlying infections:
Nurofen Plus Tablets can mask symptoms of infection, which may lead to delayed initiation of appropriate treatment and thereby worsening the outcome of the infection. This has been observed in bacterial community acquired pneumonia and bacterial complications to varicella. When Nurofen Plus Tablets are administered for fever or pain relieve in relation to infection, monitoring of infection is advised. In non-hospital settings, the patient should consult a doctor if symptoms persist or worsen. Exceptionally, varicella can be at the origin of serious cutaneous and soft tissue infectious complications. It is advisable to avoid use of ibuprofen in case of varicella.
Impaired female fertility: There is some evidence that drugs which inhibit cyclo-oxygenase/prostaglandin synthesis may cause impairment of female fertility by an effect on ovulation. This is reversible on withdrawal of treatment.
Do not take concurrently with any other codeine containing compounds.
Care is advised in the administration of codeine to patients with hypotension, asthma, decreased respiratory reserve, acute respiratory depression, obstructive airways disease, prostatic hyperplasia, hypothyroidism, adrenocortical insufficiency, shock, head injuries, conditions in which intracranial pressure is raised, obstructive bowel disorders, acute abdominal conditions (e.g. peptic ulcer), recent gastrointestinal surgery, paralytic ileus, gallstones, myasthenia gravis, a history of peptic ulcer or convulsions and also in patients with a history of drug abuse and in acute alcoholism.
Elderly patients may metabolise or eliminate opioid analgesics more slowly than younger adults. Codeine should be used with caution in the elderly and debilitated patients as they may be more susceptible to the respiratory depressant effects.
Opioid use disorder (abuse and dependence): Tolerance, physical and psychological dependence and opioid use disorder (OUD) may develop upon repeated administration of opioids such as codeine. Abuse or intentional misuse of may result in overdose and/or death.
Serious clinical outcomes, including fatalities, have been reported in association with abuse and dependence with codeine/ibuprofen combinations, particularly when taken for prolonged periods at higher than recommended doses. These have included reports of gastrointestinal perforations, gastrointestinal haemorrhages, severe anaemia, renal failure, renal tubular acidosis and severe hypokalaemia associated with the ibuprofen component.
Patients should be informed about the risks and signs of OUD as well as serious clinical outcomes. If these signs occur, patients should be advised to contact their doctor.
Withdrawal symptoms, such as restlessness and irritability may occur once the drug is stopped.
If you are pregnant or are being prescribed medicines, seek the advice of a doctor before taking this product (see section 4.3).
CYP2D6 metabolism: Codeine is metabolised by the liver enzyme CYP2D6 into morphine, its active metabolite. If a patient has a deficiency or is completely lacking this enzyme an adequate analgesic effect will not be obtained. Estimates indicate that up to 7% of the Caucasian population may have this deficiency. However, if the patient is an extensive or ultra-rapid metaboliser there is an increased risk of developing side effects of opioid toxicity even at commonly prescribed doses. These patients convert codeine into morphine rapidly resulting in higher than expected serum morphine levels.
General symptoms of opioid toxicity include confusion, somnolence, shallow breathing, small pupils, nausea, vomiting, constipation, and lack of appetite. In severe cases this may include symptoms of circulatory and respiratory depression, which may be life-threatening and very rarely fatal. Estimates of prevalence of ultra-rapid metabolisers in different populations are summarized below:
| Population | Prevalence % |
|---|---|
| African/Ethiopian | 29% |
| African American | 3.4% to 6.5% |
| Asian | 1.2% to 2% |
| Caucasian | 3.6% to 6.5% |
| Greek | 6.0% |
| Hungarian | 1.9% |
| Northern European | 1 to 2% |
Post-operative use in children: There have been reports in the published literature that codeine given post-operatively in children after tonsillectomy and/or adenoidectomy for obstructive sleep apnoea, led to rare, but life-threatening adverse events including death (see also section 4.3). All children received doses of codeine that were within the appropriate dose range; however there was evidence that these children were either ultra-rapid or extensive metabolisers in their ability to metabolise codeine to morphine.
Children with compromised respiratory function: Codeine is not recommended for use in children in whom respiratory function might be compromised including neuromuscular disorders, severe cardiac or respiratory conditions, upper respiratory or lung infections, multiple trauma or extensive surgical procedures. These factors may worsen symptoms of morphine toxicity.
Central Sleep Apnoea: Opioids can cause sleep-related breathing disorders including central sleep apnoea (CSA) and sleep related hypoxemia particularly at higher doses. Whilst evidence of this is limited with codeine use, it is recommended to consider decreasing the codeine dosage in patients who present with CSA disorder.
Hyperalgesia: Hyperalgesia has been reported with the use of opioids, particularly following long-term use and/or at high doses. There is limited evidence of this with codeine use. Hyperalgesia may resolve with opioid dose reduction, discontinuation or switching to a different opioid.
Keep out of the sight and reach of children.
Each tablet contains 1.26 to 1.89mg (0.05 to 0.08 mmol) of sodium per tablet, this is to say it is essentially sodium free.
If you are elderly or particularly if you are receiving regular treatment from your doctor, consult your doctor before taking this medicine.
The following drug-drug interactions are known to occur in association with the ibuprofen active substance in the product.
Ibuprofen (like other NSAIDs) should not be used in combination with:
Acetylsalicylic acid (aspirin): unless low-dose aspirin (not above 75mg daily) has been advised by a doctor, as this may increase the risk of adverse reactions especially in the gastrointestinal tract (see section 4.4). Concomitant administration of ibuprofen and acetylsalicylic acid is not generally recommended because of the potential of increased adverse effects.
Experimental data suggest that ibuprofen may competitively inhibit the effect of low dose acetylsalicylic acid on platelet aggregation when they are dosed concomitantly. Although there are uncertainties regarding the extrapolation of these data to the clinical situation, the possibility that regular, long-term use of ibuprofen may reduce the cardioprotective effect of low-dose acetylsalicylic acid cannot be excluded. No clinically relevant effect is considered to be likely for occasional ibuprofen use (see section 5.1).
Other NSAIDs including cyclooxygenase-2 selective-inhibitors: Avoid concomitant use of two or more NSAIDs as this may increase the risk of adverse effects (see section 4.4).
The product should be used with caution in combination with:
CYP2D6 Inhibitors: Dependence of codeine hypoalgesia on morphine formation via CYP2D6 makes this effect liable to interaction with drugs that are inhibitors of CYP2D6. Examples of potent inhibitors of CYP2D6 are quinidine, some selective serotonin reuptake inhibitors, some neuroleptics and ritornavir.
Anti-coagulants: NSAIDs may enhance the effects of anti-coagulants, such as warfarin (see section 4.4).
Antihypertensives (ACE inhibitors and Angiotensin II Antagonists) and diuretics: NSAIDs may diminish the effects of these drugs. In some patients with compromised renal function (e.g. dehydrated patients or elderly patients with compromised renal function) the co-administration of an ACE inhibitor or Angiotensin II antagonist and agents that inhibit cyclo-oxygenase may result in further deterioration of renal function, including possible acute renal failure, which is usually reversible. These interactions should be considered in patients taking a cyclooxygenase-2 selective inhibitors concomitantly with ACE inhibitors or angiotensin II antagonists. Therefore, the combination should be administered with caution, especially in the elderly. Patients should be adequately hydrated and consideration should be given to monitoring of renal function after initiation of concomitant therapy, and periodically thereafter. Diuretics can increase the risk of nephrotoxicity of NSAIDs. The hypotensive actions of diuretics and anti-hypertensive agents may be potentiated when used concurrently with opioid analgesics.
Corticosteroids: increased risk of gastrointestinal ulceration or bleeding (see section 4.4).
Anti-platelet agents and selective serotonin reuptake inhibitors (SSRIs): increased risk of gastrointestinal bleeding (see section 4.4)
Cardiac glycosides: NSAIDs may exacerbate cardiac failure, reduce GFR and increase plasma glycoside levels.
Lithium: there is evidence for potential increases in plasma levels of lithium.
Methotrexate: there is evidence for potential increases in plasma levels of methotrexate.
Ciclosporin: Increased risk of nephrotoxicity.
Mifepristone: NSAIDs should not be used for 8-12 days after mifepristone administration as NSAIDs can reduce the effect of mifepristone.
Tacrolimus: Possible increased risk of nephrotoxicity when NSAIDs are given with tacrolimus.
Zidovudine: Increased risk of haematological toxicity when NSAIDs are given with Zidovudine. There is evidence of an increased risk of haemarthroses and haematoma in HIV haemophiles receiving concurrent treatment with zidovudine and ibuprofen.
Quinolone antibiotics: Animal data indicate that NSAIDs can increase the risk of convulsions associated with quinolone antibiotics. Patients taking NSAIDs and quinolones may have an increased risk of developing convulsions.
The following drug-drug interactions are known to occur in association with the Codeine active substance in the product:
Monoamine oxidase inhibitors: CNS depression or excitation may occur if codeine is given to patients receiving monoamine oxidase inhibitors, or within two weeks of stopping treatment with them (see section 4.3).
Moclobemide: risk of hypertensive crisis.
Hydroxyzine: Concurrent use of hydroxyzine (anxiolytics) with codeine may result in increased analgesia as well as increased CNS depressant, sedative and hypotensive effects.
Central Nervous System Depressants: The depressant effects of codeine are enhanced by depressants of the central nervous system such as other opioids, alcohol, anaesthetics, hypnotics, sedatives, tricyclic antidepressants or antipsychotics and phenothiazines.
Abiraterone: Abiraterone might reduce analgesic effect of codeine by CYP2D6 inhibition.
Antidiarrhoeal and Anti-peristaltic agents: Concurrent use of codeine with antidiarrhoeal and antiperistaltic agents such as loperamide and kaolin may increase the risk of severe constipation.
Antimuscarinics: Concomitant use of antimuscarinics or medications with muscarinic action, e.g., atropine and some antidepressants may result in an increased risk of severe constipation which may lead to paralytic ileus and/or urinary retention.
Neuromuscular Blocking Agents: The respiratory depressant effect caused by neuromuscular blocking agents may be additive to the central respiratory depressant effects of opioid analgesics.
Quinidine: Quinidine can inhibit the analgesic effect of codeine.
Mexiletine: Codeine may delay the absorption of mexiletine and thus reduce the antiarrhythmic effect of the latter.
Metoclopramide, cisapride and domperidone: Codeine may antagonise the gastrointestinal effects of metoclopramide, cisapride and domperidone.
Cimetidine: Cimetidine inhibits the metabolism of opioid analgesics resulting in increased plasma concentrations.
Naxolone: Naxolone antagonises the analgesic, CNS and respiratory depressant effects of opioid analgesics. Naltrexone also blocks the therapeutic effect of opioids.
Interference with laboratory tests: Opioid analgesics interfere with a number of laboratory tests including plasma amylase, lipase, bilirubin, alkaline phosphatase, lactate dehydrogenase, alanine aminotransferase and aspartate aminotransferase. Opioids may also interfere with gastric emptying studies as they delay gastric emptying and with hepatobiliary imaging using technetium Tc 99m disofenin as opioid treatment may cause constriction of the sphincter of Oddi and increase biliary tract pressure.
Inhibition of prostaglandin synthesis may adversely affect the pregnancy and/or the embryo/foetal development. Data from epidemiological studies suggest an increased risk of miscarriage and of cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk for cardiovascular malformation was increased from less than 1%, up to approximately 1.5%. The risk is believed to increase with dose and duration of therapy.
In animals, administration of a prostaglandin synthesis inhibitor has been shown to result in increased pre- and postimplantation loss and embryo-foetal lethality. In addition, increased incidences of various malformations, including cardiovascular, have been reported in animals given a prostaglandin synthesis inhibitor during the organogenetic period.
From the 20th week of pregnancy onward, ibuprofen use may cause oligohydramnios resulting from foetal renal dysfunction. This may occur shortly after treatment initiation and is usually reversible upon discontinuation. In addition, there have been reports of ductus arteriosus construction following treatment in the second trimester, most of which resolved after treatment cessation. Therefore, during the first and second trimester of pregnancy, ibuprofen should not be given unless clearly necessary. If ibuprofen is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low and duration of treatment as short as possible. Anti-natal monitoring for oligohydramnios and ductus arteriosus constriction should be considered after exposure for several days from gestational week 20 onward. Treatment should be discontinued if oligohydramnios or ductus arteriosus constriction are found.
During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the foetus to:
the mother and the neonate, at the end of pregnancy, to:
Consequently, ibuprofen is contraindicated during the third trimester of pregnancy (see section 4.3).
This product should not be used during breastfeeding (see section 4.3). At normal therapeutic doses codeine and its active metabolite may be present in breast milk at very low doses and is unlikely to adversely affect the breast fed infant. However, if the patient is an ultra-rapid metaboliser of CYP2D6, higher levels of the active metabolite, morphine, may be present in breast milk and on very rare occasions may result in symptoms of opioid toxicity in the infant, which may be fatal.
See section 4.4 regarding female fertility.
Patients may become dizzy and sedated with Nurofen Plus Tablets. Rare side effects may include convulsions, hallucinations, blurred or double vision and orthostatic hypotension (see section 4.8). If affected, patients should not drive or operate machinery.
The list of the following adverse effects relates to those experienced with Ibuprofen and Codeine at OTC doses (maximum 1200mg ibuprofen per day), in short-term use. In the treatment of mild to moderate pain and fever. In the treatment of other indications or under long-term treatment, additional adverse effects may occur.
Adverse events which have been associated with Ibuprofen and Codeine are given below tabulated by System Organ Class (SOC) and frequency. Frequencies are defined as: very common (≥1/10), common (≥1/100 and <1/10), uncommon (≥1/1000 and <1/100), rare (≥1/10,000 and <1/1000), very rare (<1/10,000) and not known (cannot be estimated from the available data). Within each frequency grouping, adverse events are presented in order of decreasing seriousness.
| System Organ Class | Frequency | Adverse Events |
|---|---|---|
| Blood and Lymphatic System Disorders | Very rare | Haematopoietic disorders1 |
| Immune system disorders | Uncommon | Hypersensitivity reactions with urticaria and pruritus2 |
| Very rare | Severe hypersensitivity reactions. Symptoms could be: facial, tongue and throat swelling, dyspnoea, tachycardia, and hypotension (anaphylaxis, angioedema or severe shock)2 | |
| Metabolism and Nutrition Disorders | Not known | Decreased appetite |
| Psychiatric Disorders | Not known | Depression, hallucination, confusional state, dependence, mood altered, restlessness, nightmares. |
| Nervous System Disorders | Uncommon | Headache |
| Very rare | Aseptic meningitis3 | |
| Not known | Dizziness, drowsiness, convulsion, intracranial pressure increased, dyskinesia | |
| Eye Disorders | Very rare | Vision blurred |
| Not known | Diplopia | |
| Ear and Labyrinth disorders | Not known | Vertigo |
| Cardiac Disorders | Very rare | Cardiac failure and oedema4. |
| Not known | Bradycardia, palpitations | |
| Vascular Disorders | Very rare | Hypertension4 |
| Not known | Orthostatic hypotension | |
| Respiratory, Thoracic and Mediastinal Disorders | Not known | Respiratory tract reactivity comprising asthma, bronchospasm or dyspnoea2 Respiratory depression, cough suppression |
| Gastro-intestinal Disorders | Uncommon | Abdominal pain, nausea and dyspepsia. Exacerbation of colitis and Crohn’s disease, gastritis5,6. |
| Rare | Diarrhoea, flatulence, constipation and vomiting. | |
| Very rare | Peptic ulcer, gastrointestinal perforation or gastrointestinal haemorrhage, melaena, and haematemesis7. Mouth ulceration. | |
| Not known | Dry mouth | |
| Hepatobiliary Disorders | Very rare | Liver disorder8 |
| Not known | Biliary colic | |
| Skin and Subcutaneous Tissue Disorders | Uncommon | Skin rash2 |
| Very rare | Severe forms of skin reactions such as erythema multiforme can occur. Bullous reactions including Stevens-Johnson syndrome and toxic epidermal necrosis2. | |
| Not known | Flushing. Drug reaction with eosinophilia and systemic symptoms (DRESS syndrome). Acute generalised exanthematous pustulosis (AGEP) Photosensitivity reactions | |
| Musculoskeletal and Connective Tissue Disorders | Not known | Muscle rigidity |
| Renal and Urinary Disorders | Very rare | Acute renal failure9 |
| Not known | Ureteric colic, dysuria10. Renal tubular acidosis11 | |
| General and Administration Site Conditions | Not known | Hypothermia, hyperhidrosis, irritability, fatigue, malaise. |
| Investigations | Very rare | Haemogloblin decreased, urea renal clearance decreased. |
| Infections and infestations | Very rare | Exacerbation of infections related inflammation (e.g. development of necrotizing fasciitis), in exceptional cases, severe skin infections and soft-tissue complication may occur during a varicella infection. |
1 Examples include anaemia, leucopenia, thrombocytopenia, pancytopenia and agranulocytosis. First signs are fever, sore throat, superficial mouth ulcers, flu-like symptoms, severe exhaustion, nose and skin bleeding, and bruising.
2 Hypersensitivity reactions: These may consist of (a) non-specific allergic reactions and anaphylaxis, (b) respiratory tract reactivity, including asthma, aggravated asthma, bronchospasm, and dyspnoea, or © various skin reactions, including pruritius, urticaria, purpura, angioedema and, more rarely, exfoliative and bullous dermatoses, including toxic epidermal necrolysis, Stevens-Johnson Syndrome and erythema multiforme.
3 The pathogenic mechanism of drug-induced aseptic meningitis is not fully understood. However, the available data on NSAID-related aseptic meningitis points to a hypersensitivity reaction (due to a temporal relationship with drug intake, and disappearance of symptoms after drug discontinuation). Single cases of symptoms of aseptic meningitis (such as stiff neck, headache, nausea, vomiting, fever or disorientation) have been observed during treatment with ibuprofen in patients with existing auto-immune disorders (such as systemic lupus erythematosus and mixed connective tissue disease).
4 Clinical studies suggest that use of Ibuprofen, particularly at a high doses (2400 mg/day) may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke) (see section 4.4).
5 The adverse events observed most often are gastrointestinal in nature.
6 See Section 4.4.
7 Sometimes fatal.
8 Especially in long-term treatment.
9 Especially in long-term use, associated with increased serum urea concentrations and oedema. Also includes papillary necrosis.
10 Increased frequency, decrease in amount.
11 Renal tubular acidosis and hypokalaemia have been reported in the post-marketing setting typically following prolonged use of the ibuprofen component at higher than recommended doses due to dependence on the codeine component.
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance, Earlsfort Terrace, IRL – Dublin 2, Tel: +353 1 6764971, Fax: +353 1 6762517, Website: www.hpra.ie, e-mail: medsafety@hpra.ie.
Not applicable.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
